

Supplementary Table 2: The TNM stage characteristics and correlations between LVI and preoperative PSA and pathological parameters

Study	TNM stages and GS characteristics (staging system)	Number (%) of positive LVI	Preoperative PSA (ng ml ⁻¹)		P*	pT stage >pT3/total		ECE Positive/total		SVI Positive/total		GS ≥7 GS/total		pN stage pN+/total	
			LVI (+)	LVI (-)		LVI (+)	LVI (-)	LVI (+)	LVI (-)	LVI (+)	LVI (-)	LVI (+)	LVI (-)	LVI (+)	LVI (-)
Yee <i>et al.</i> ³⁴	pT2-4, pN0-1 GS (<7, 7, >7) (2002 AJCC)	129/1298 (9.9)	7.3 (4.9-11.3)	5.1 (3.7-7.1)	<0.001	60/80	315/1115	97/129	348/1169	49/129	41/1169	123/129	855/1169	49/129	45/1169
Lee <i>et al.</i> ³²	pT2-4, pN0-1 GS (<7, 7, >7) (2002 AJCC)	40/361 (11.1)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Cho <i>et al.</i> ³¹	pT2-3, pNx GS (<7, 7, >7) (2002 AJCC)	16/167 (9.6)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Jeon <i>et al.</i> ³⁰	pT2-3, pN0-1 GS (<7, 7, >7) (2002 AJCC)	41/237 (17.3)	16.4 (2.7-98.0)	10.5 (0.2-86.6)	0.002	30/41	62/196	26/41	58/196	17/41	15/196	39/41	144/194	NA	NA
Whitmore <i>et al.</i> ²⁸	pT2-4, pN0-1 GS (7) (2002 AJCC)	12/214 (5.6)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Yamamoto <i>et al.</i> ²⁹	pT3a, pN0 GS (<7, 7, >7) (1997 AJCC)	26/94 (27.7)	12.8 (3.5-59.0)	8.55 (0.5-75.0)	0.022	26/26	94/94	NA	NA	0/26	0/68	23/26	42/68	0/26	0/68
May <i>et al.</i> ²⁶	pT2-3b, pN0 GS (<7, 7, >7) (1997 AJCC)	42/412 (10.2)	22.6 (6.4-151)	10.9 (0.1-51)	<0.001	27/42	86/370	NA	NA	NA	NA	33/42	136/370	0/42	0/370
Hofer <i>et al.</i> ²³	pTx, pN1 GS (<7, 7, >7) (2002 AJCC)	29/116 (25.0)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	29/29	116/116
Antunes <i>et al.</i> ²¹	pT2-3, pN0 GS (<7, 7, >7) (1992 AJCC)	47/428 (11.0)	10.6 (8.6-13.1)	8 (7.5-8.5)	0.004	24/47	95/381	43/47	189/381	6/47	17/381	35/47	136/381	0/47	0/381
Loeb <i>et al.</i> ²⁴	pTx, pN0-1 GS (<7, 7, >7) (NA)	118/1709 (6.9)	5.8	4.5	<0.0001	78/118	346/1573	55/115	196/1633	26/118	38/1591	70/117	473/1578	7/118	4/1591
Brooks <i>et al.</i> ²²	pTx, pN0-1 GS (<7, 7, >7) (NA)	18/160 (11.3)	10.9 (4.7-40.7)	17.7 (1.3-217)	0.44	NA	NA	13/18	80/140	10/18	30/134	15/17	86/130	3/18	8/142
Cheng <i>et al.</i> ²⁰	pT2-3, pN0-1 GS (<7, 7, >7) (1997 AJCC)	106/504 (21.0)	NA	NA	NA	73/106	83/398	63/106	74/398	36/106	31/398	102/106	220/398	11/106	7/398
Shariat <i>et al.</i> ¹⁹	pTx, pN0-1 GS (<7, 7, >7) (1997 AJCC)	32/630 (5.1)	7.8 (4.0-99.0)	6.0 (0.1-52.0)	0.04	NA	NA	26/32	156/598	22/32	35/598	31/32	343/598	8/32	2/598
Ito <i>et al.</i> ¹⁷	pT2-3, pN0 GS (<7, 7, >7) (1997 AJCC)	38/82 (46.3)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0/38	0/44
de la Taille <i>et al.</i> ¹⁴	pT2-3, pN0-1 GS (<7, 7, >7) (NA)	30/241 (12.4)	NA	NA	NA	20/30	56/211	21/30	48/211	7/30	11/211	28/30	92/211	NA	NA
van den Ouden <i>et al.</i> ¹³	pT2-4, pN0-1 GS (<7, 7, >7) (1992 AJCC)	33/273 (12.1)	NA	NA	NA	32/33	155/240	30/33	145/240	21/33	57/240	16/33	45/240	5/33	22/240
Leng <i>et al.</i> ³⁷	pT2-4, pN0-1 GS (7) (2010 AJCC)	40/166 (24.1)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Chromceki <i>et al.</i> ³⁵	pTx, pN0-1 GS (<7, 7, >7) (NA)	8/102 (7.8)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Quinn <i>et al.</i> ¹⁶	pT2-4, pN0-1 GS (<7, 7, >7) (1992 AJCC)	38/731 (5.2)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Huang <i>et al.</i> ²⁵	pT2-4, pN0-1 GS (<7, 7, >7) (1997 AJCC)	17/111 (15.3)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Jung <i>et al.</i> ³³	pT2-3, pN0-1 GS (<7, 7, >7) (2002 AJCC)	27/407 (6.6)	12.83 (2.40-30.78)	9.83 (1.76-83.23)	0.075	17/27	108/380	7/27	50/380	11/27	58/380	23/27	224/380	3/27	9/380
Ferrari <i>et al.</i> ¹⁸	pTx, pN0-1 GS (<7, 7, >7) (NA)	110/620 (17.7)	NA	NA	NA	NA	NA	70/110	149/509	31/109	26/510	108/110	393/504	15/108	24/506
Luo <i>et al.</i> ³⁶	pTx, pN0-1 GS (<7, 7, >7) (NA)	18/87 (20.7)	NA	NA	NA	NA	NA	14/18	26/69	10/18	28/69	9/18	8/69	2/18	3/69
Herman <i>et al.</i> ¹⁵	pT3, pN0 GS (<7, 7, >7) (NA)	91/172 (52.9)	NA	NA	NA	NA	NA	63/91	97/172	37/91	26/172	76/91	116/172	0/91	0/172
Baydar <i>et al.</i> ²⁷	pT2-3, pN0-1 GS (<7, 7, >7) (NA)	11/71 (15.5)	NA	NA	NA	11/11	36/60	11/11	36/59	7/11	11/60	11/11	42/60	4/11	1/58

*A P value represent a statistically difference. TNM: tumor-node-metastasis; ECE: extracapsular extension; SVI: seminal vesicle involvement; LVI: lymphovascular invasion; PSA: prostate-specific antigen; pT: pathological tumor; pN: pathological node; AJCC: American Joint Committee on Cancer and the International Union Against Cancer; GS: Gleason score; NA: not available